Greenwich LifeSciences Reports $5.7 Million Net Loss in Q1 2026

Greenwich LifeSciences, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $5.7 million, compared to a net loss of $2.7 million for the same period in 2025. The company did not generate any revenue during this quarter, consistent with its ongoing status as a clinical-stage biopharmaceutical firm focused on developing immunotherapy for breast cancer. The loss per share for the quarter was $0.39, an increase from $0.21 in the prior year. The company's total operating expenses rose significantly to $5.7 million, up from $2.8 million in the previous year, primarily driven by increased research and development costs.

In terms of financial position, Greenwich LifeSciences reported total assets of $10.5 million as of March 31, 2026, a substantial increase from $6.2 million at the end of 2025. This growth was largely attributed to a successful At The Market (ATM) offering, where the company raised approximately $9.0 million in net proceeds from the sale of 367,547 shares of common stock. The company’s cash reserves also improved, rising to $10.5 million from $6.2 million at the end of the previous fiscal year. Total liabilities decreased slightly to $5.2 million from $5.8 million, reflecting a reduction in accounts payable.

Operationally, Greenwich LifeSciences is advancing its Phase III clinical trial, Flamingo-01, which is evaluating its product candidate GLSI-100 aimed at preventing breast cancer recurrences. The company is expanding this trial into Europe, with plans to open up to 150 sites globally. The increase in research and development expenses was primarily due to heightened clinical trial activities. The company continues to rely on third-party contract manufacturers for its clinical trial materials, which is a critical aspect of its operational strategy.

As of the end of March 2026, the company had 14,665,993 shares of common stock issued and outstanding, reflecting an increase from 14,298,446 shares at the end of 2025. The company remains classified as a smaller reporting company and a non-accelerated filer, which allows it to take advantage of certain regulatory exemptions. Looking ahead, Greenwich LifeSciences anticipates continued net losses as it invests in its clinical trials and infrastructure necessary for future commercialization efforts. The company has indicated that it will require additional capital to support its long-term operating requirements, emphasizing the importance of its ongoing fundraising efforts.